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The Ca2+-mobilizing potency of a-thrombin 
and thrombin-receptor-activating peptide on human platelets 
Concentration and time effects of thrombin-induced Ca2+ signaling 
Johan W. M. HEEMSKERK, Marion A. H. FEIJGE, Lidewij HENNEMAN, Jan ROSING and H. Coenraad HEMKER 
Departments of Biochemistry and Human Biology, Maastricht University, The Netherlands 
(Received 24 March/l3 August 1997) - EJB 97 0415/1 
In single platelets and in suspensions of platelets, a-thrombin evokes dose-dependent, transient in- 
creases in cytosolic Caz+ concentration, [Ca’+],, which are more prolonged than the [Ca’+], transients 
evoked by other platelet agonists such as the thrombin-receptor-activating hexapeptide SFLLRN, throm- 
boxane A, analog U46619, and ADP. As a quantity taking into account both the magnitude and length 
of the Ca2+ response, we defined the Caz+-mobilizing potency (CMP) of an agonist as the integrated rise 
in [Ca2+], during the time of the Caz+ signal. It was observed that: (a) the CMP increased with the agonist 
concentration in a saturating way, its maximal value being about four-times higher with a-thrombin than 
with SFLLRN; (b) the high CMP of a-thrombin was for only a small part due to endogenous production 
of ADP or thromboxane, and was mainly a consequence of prolonged influx of external Ca2+ ; (c) the 
CMP declined when a-thrombin was inactivated during the course of the Ca2+ signal; (d) CMP values 
increased with the agonist concentration upon sequential addition of increasing amounts of a-thrombin or 
SFLLRN; (e) when a-thrombin was gradually added to the platelets or formed by an in situ reconstituted 
prothrombinase system (with factor Xa, factor Va, and prothrombin), integrated CaZ+ responses were a 
function of the product of the a-thrombin concentration and the time of its presence. However, in these 
cases, the final CMP values were independent of the rate of a-thrombin addition or formation. We con- 
clude that a-thrombin-induced Ca2+ signals in platelets rely largely upon Ca2+ influx, are not, or only 
slightly, subjected to homologous desensitization, and reflect the enzymatic capacity of a-thrombin to 
cleave protease-activated receptors. Thus, the high and prolonged Caz+ signal induced by a-thrombin is 
due to continuous receptor cleavage without desensitizing effects of previously cleaved receptors. 
Keywords: calcium mobilization; platelets ; protease-activated receptor; a-thrombin ; thrombin-receptor- 
activating peptide. 
a-Thrombin is a potent platelet-activating agonist that is lo- 
cally formed at hemostatic sites in the blood stream as a result 
of the coagulation process. In flowing blood, platelets are likely 
to be exposed to only short-lasting waves of this agonist be- 
cause, once produced, a-thrombin is almost immediately inacti- 
vated by anti-thrombins in plasma with a velocity proportional 
to its concentration [ 11. Accordingly, at hemostatic sites, both 
the local a-thrombin concentration and the time during which it 
is active may determine the activating effect on platelets. 
The identity of the functional a-thrombin receptors on plate- 
lets is still debated. In 1991, a tethered ligand-linked receptor 
for a-thrombin was identified, which is now designated as the 
protease-activated receptor type 1. After cleavage by a-throm- 
bin, this receptor activates itself through the newly exposed N- 
terminal ligand [2]. On the basis of experiments with synthetic 
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Abbreviations. [Ca”],, cytosolic Ca2+ concentration: CMP, Ca2+- 
mobilizing potency: Ins(1,4,S)P,, inositol 1,4,5-trisphosphate; U46619, 
(SZ,9,,,13E,15S)-9,11 -(epoxymethano)pros-5,13-dien-1-oic acid. 
Enzymes. Apyrase (EC 3.6.1.5); coagulation factor Xa (EC 
3.4.21.6); phospholipase C (EC 3.1.4.3): thrombin (EC 3.4.21.5). 
thrombin-receptor-activating peptides such as SFLLRN, which 
bind to this receptor in the absence of proteolysis, it was initially 
concluded that the tethered ligand receptor mediates many or all 
of the effects of a-thrombin on human platelets [3-51. However, 
later studies showed that these mimicking peptides were often 
less active than a-thrombin itself [6-91, suggesting that other a- 
thrombin receptors may also exist. Experiments with antibodies 
against glycoprotein Ib and with platelets from Bernard-Soulier 
patients, deficient in this glycoprotein, have suggested that (sub- 
sets of) glycoprotein Ib may act as high-affinity receptors for a- 
thrombin [lo, ll]. On the other hand, it has been shown that 
the platelet-stimulating effect of a-thrombin is unrelated to the 
equilibrium binding of a-thrombin to platelets, but is solely due 
to its proteolytic effect on (receptor) substrates on the platelet 
membrane [12]. This would imply that not only the a-thrombin 
concentration, but also of the time of its action determines the 
degree of platelet activation. A second type of protease-activated 
receptor for a-thrombin has recently been cloned from human 
tissue [13], although it is still unclear whether this receptor is 
functional in platelets. 
Regardless of the identity of the platelet receptors involved, 
a-thrombin is known to be a potent stimulator of phospholipase 
C-p and - y  isoforms, causing substantial and prolonged forma- 
tion of inositol 1,4,5-trisphosphate [Ins(l,4,5)P3] 13, 14- 171 and 
a high increase in cytosolic [Ca”], [9-11, 18-20]. a-Throm- 
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bin-evoked increases in inositolphosphates [3] and [Ca'+], [ 8, 
181 are inhibitable by post-addition of thrombin active-site in- 
hibitors, suggesting that the continuous presence of enzymatic 
a-thrombin is required for generation of these second messen- 
gers. In studies with transfected Rat 1 fibroblasts, equipped with 
labeled, recombinant protease-activated receptors for a-throm- 
bin, it was observed that the rate and extent of second messenger 
generation in response to a-thrombin was related to the rate of 
proteolytic cleavage of the thrombin receptors [21]. Although 
the situation in platelets with several types of native thrombin 
receptors is likely to be more complex, the fibroblast model 
rightly points to the existence of both an a-thrombin concentra- 
tion-dependent and time-dependent component in Ins( 1,4,5)P, 
formation and CaZ+ mobilization. In agreement with this, we 
have earlier shown that individual platelets, when activated with 
a-thrombin, show spiking variations in [Ca'+], that are dose- 
dependent and often of prolonged duration [22, 231. 
Taken together, in coagulating plasma with varying concen- 
trations of a-thrombin, two time-dependent processes may play 
a role in a-thrombin-induced Ca'+ mobilization: (a) the duration 
of the exposure of platelets to a-thrombin, and (b) the length of 
the Ca2+ signal elicited by a certain concentration of a-thrombin 
at a certain time. To study the relevance of the time component, 
we measured the CaZ+ responses of platelets that were exposed 
to variable concentrations of a-thrombin or SFLLRN. The a- 
thrombin concentration was changed here by either continuous 
infusion of preformed a-thrombin or by gradual generation of a- 
thrombin using a reconstituted prothrombinase complex, con- 
sisting of factor Xa, factor Va and prothrombin [24, 251. The 
Ca'+-mobilizing potency (CMP) of a-thrombin or other agonists 
was then defined as the time integral of the rise in [Ca"], over 
the time period where the agonist was active. The results show 
that a-thrombin has a high CMP in comparison to SFLLRN and 
other agonists. They also indicate that the a-thrombin-evoked 
Ca'+ signal, at any time, is essentially determined by the a- 
thrombin concentration at that time. However, the integrated 
CaZ+ signal (CMP) appears to be determined by the product of 
a-thrombin concentration and time of its action, suggesting this 
parameter reflects the extent of proteolytic cleavage of a-throm- 
bin-degradable receptors. 
EXPERIMENTAL PROCEDURES 
Materials. Human prothrombin and a-thrombin (activity 
> 3000 NIH U/mg protein; 1 U/ml equivalent to 11.4 nM) and 
clotting factor Xa and factor Va were purified to homogeneity, 
as described elsewhere [26, 271. Human a-thrombin of the same 
purity was also bought from Sigma. ADP, apyrase, fibrinogen, 
dioleoylglycerophosphocholine, dioleoylglycerophosphoserine, 
prostaglandin E,, and the thromboxane AJprostaglandin H, ana- 
log (SZ,9,,13E,15S)-9,1 l -(epoxymethano)pros-5,13-dien-l -oic 
acid (U46619) were also from Sigma. The thrombin-receptor- 
activating hexapeptide, SFLLRN, which was purified to homo- 
geneity by HPLC, was obtained from IHB (Academic Hospital 
Leiden, The Netherlands). Human antithrombin I11 was 
purchased from Enzyme Research Laboratories ; recombinant 
human hirudin was from Ciba-Geigy ; FPR chloromethylketone 
(H-Phe-Pro-Arg chloromethylketone) was from Calbiochem. 
Fura-2 acetoxymethyl ester was bought from Molecular Probes. 
The a-thrombin-cleavable chromogenic substrate S2238 was 
from Chromogenix. Other chemicals were reagent grade and 
were obtained from sources as described before [19]. 
Preparation of platelets and loading with fura-2. Platelet- 
rich plasma was prepared from blood freshly obtained from 
healthy donors, who had not taken medication during the preced- 
ing two weeks [23]. Platelets in plasma were incubated with 
3 pM fura-2 acetoxymethyl ester at 37°C for 45 min. Lysine 
acetyl salicylate (aspirin) was added at a concentration of 
100 pM, where indicated. The platelets were then sedimented by 
centrifugation at 630 g for 15 min, washed twice in the presence 
of apyrase (0.1 U ADPase/ml), and resuspended in buffer A, 
pH 7.45 (37"C), containing 136 mM NaCl, 10 mM glucose, 
5 mM Hepes, 2.7 mM KCl, 2 mM MgCl,, and 0.05% (mass/ 
vol.) bovine serum albumin [28]. Suspensions were adjusted to 
1 X loR platelets/ml. 
Activation of platelets in suspension. Washed, fura-2- 
loaded platelets (2X 108/2 ml buffer A) were slowly stirred in a 
cuvette placed in a thermostated (37 "C) spectrofluorometer. 
Where indicated, a-thrombin or other agonists were added from 
concentrated stock solutions. In other experiments, a-thrombin 
or SFLLRN was slowly infused into the stirred platelet suspen- 
sion. The flow was generated by a motor-driven pump (Harvard 
Apparatus, Vel, Belgium) pushing the piston of a 100-pl silicon- 
ized, pressure-lock syringe filled with a solution of agonist in 
buffer A, kept at 37°C. In some experiments, a-thrombin was 
generated from prothrombin in situ. In this case, fura-2-loaded 
platelets (2X 10V2 ml) were incubated with 2 mM CaCI, and the 
desired concentrations of purified coagulation factors Va and Xa 
under slowly stirring at 37 "C. Prothrombinase activation was 
started by the addition of 0.5 pM prothrombin. 
Activation of single, immobilized platelets. Fura-2-loaded 
platelets were immobilized on fibrinogen-coated glass coverslips 
in the presence of 10 pM RGDS, apyrase (0.2 U ADPase/ml), 
and 0.1 pM prostaglandin E,, as described before [23, 291. The 
bound platelets were bathed in 0.5 ml buffer A supplemented 
with 10 pM RGDS, apyrase (0.2 U ADPase/ml), and CaC1, 
(2 mM) at room temperature. Under these conditions, > 95 % of 
the platelets immobilized on fibrinogen remained low in [Ca'+], 
for at least 10 min. Agonists and antagonists were given in vol- 
umes of 0.1 ml from concentrated stock solutions in bathing me- 
dium. Thrombin was generated in situ by the addition of 
0.24 nM factor Va, 0.1 nM factor Xa, 0.5 pM prothrombin, and 
2 pM phospholipid vesicles composed of 9: 1 (mol/mol) phos- 
phatidylcholine/phosphatidylserine. 
Measurements of cytosolic [Caz+],. In suspensions of fura- 
2-loaded platelets, changes in [Caz+], were measured in a ther- 
mostated (37 "C) cuvette chamber using a Shimadzu RF-5001PC 
spectrofluorometer, basically as described before [28]. Briefly, 
samples were alternately illuminated with 340-nm and 380-nm 
light passing from an excitation monochromator (bandpasses of 
5 nm), and the fluorescent light of 510 nm was recorded after 
background subtraction. Ratio values of fluorescence at 340 nm/ 
380 nm excitation were obtained 30- 120 times/min. The cali- 
bration of fluorescence ratio to values of [CaZ+], was according 
to Grynkiewicz et al. [30]. 
In single cell experiments, changes in fura-2 fluorescence 
were measured as usual [23, 311, except that a Quanticell fluoro- 
metric video imaging system was employed (Applied Imaging, 
Sunderland, Tyne & Wear, UK). Excitation light was passed al- 
ternately through filters of 340 nm and 380 nm wavelengths, and 
the fluorescence at 505 nm was observed by an intensified 
charge-coupled device camera (Photonic Sciences, Roberts- 
bridge, Sussex, UK), working at standard video rate and con- 
nected to an inverted microscope. Fluorescence images were 
digitalized and averaged, background images were subtracted, 
and averaged ratio images (obtained every 2 s) were stored onto 
a 650-MByte read/write optical disk. Geometric regions match- 
ing individual cells were defined and analyzed for changes in 
the fluorescence ratio. Calibration of 340 nm/380 nm fluores- 
cence ratio values to [Ca"]], was not performed, because of the 
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Fig. 1. Dose-dependent effect of CMP of a-thrombin and SFLLRN. Fura-2-loaded platelets in suspension (2X 10'12 ml) were activated with 
10 nM a-thrombin (a-Thr) (A, B) or 25 pM SFLLRN (D, E) in the presence of 1 mM CaC1, or 1 mM EGTA. (A, D) Traces are given of changes 
in cytosolic [Ca'+],, after correction for the leakage of fura-2 dye out of the platelets. (B, E) Time plots are constructed of areas under the [Ca"],! 
time curves by determining the integral, Jd[Ca2'],,dt. The CMP is the value reached by this integral at the end of the Ca2+ response. Data are 
representative for at least three experiments. (C, F) Dose-dependency of CMP of a-thrombin and SFLLRN in the presence of CaCI, or EGTA. Data 
are mean values t SE (n  = 3). 
small and variable amount of fluorescence per cell and the rapid 
bleaching of the fluorescent signals [23]. 
Determination of the Caz+-mobilizing potential. The CMP 
of a platelet agonist was defined as the integral of the increase 
in [Ca'+], over the time period where the agonist is active, 
sd [Ca"], ,dt. To calculate this parameter for experiments with 
fura-2-loaded platelets in suspension, time plots were con- 
structed of agonist-evoked increases in [Ca2+ ], relative to basal 
[Ca'+], (i.e. the level before addition of agonist). These plots 
were corrected for leakage of fura-2 and bleaching of the dye, 
by subtracting the time-dependent, apparent changes in basal 
[Ca2+I1, as observed in control incubations without agonist 
(about 4 nM Ca*+/min). Complete return of [Ca'+], at the end of 
incubations with agonists was checked, if necessary, by the addi- 
tion of prostaglandin E,, which activates Ca2+ extrusion from 
the cytosol, but does not influence basal [Ca'+],. Failure to return 
to basal [Ca'+], was in most cases due to lysis of some of the 
platelets, as was verified by measuring the release of lactate de- 
hydrogenase [28]. 
For the Ca2+ responses of single fura-2-loaded platelets, time 
integrals of increases in 340 n d 3 8 0  nm fluorescence were as- 
sessed without correction for leakage of probe or fluorescence 
quenching. 
Measurement of a-thrombin activity. In incubations where 
a-thrombin was added or generated, the concentration of proteo- 
lytically active a-thrombin was determined by taking samples of 
50 1.11 and measuring the chromogenic activity using the a- 
thrombin substrate, S2238 [31, 321. 
RESULTS 
Factors determining the CMP of a-thrombin and SFLLRN. 
In suspensions of fura-2-loaded platelets, agonists for GTP-bind- 
ing-protein-coupled receptors such as a-thrombin, thrombin-re- 
ceptor-activating peptide SFLLRN, thromboxane A, analog, 
U46619, and ADP evoked transient rises in cytosolic [Ca"],, 
which finally returned to basal levels. Under some conditions, 
e.g. rapid stirring at 1000rpm or with micromolar concentra- 
tions of U46619, [Ca2+], did not completely return to this basal 
level. In these cases, measurements of the release of lactate de- 
hydrogenase indicated lysis of 5-10% of the platelets. Since 
under most conditions, however, platelet agonists evoked essen- 
tially terminating Caz+ signals, it was possible to determine the 
accumulative rises in [Ca2+], during the response, i.e. the time 
integral s d  [Ca*+],,dt. The CMP of a certain agonist was subse- 
quently defined as the maximal value reached by this integral at 
the end of the response. It should be noted that calculation of 
the CMP required correction for leakage of fura-2 dye out of the 
platelets and, if applicable, for lysis of platelets (see Experimen- 
tal Procedures section). 
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Table 1. CMP of saturating doses of platelet agonists in the presence 
and absence of extracellular CaCI,. Fura-2-loaded platelets (2X loK/ 
2 ml) were activated with a-thrombin (40 nM), SFLLRN (100 pM), ADP 
(20 pM) or U46619 (1 pM) in the presence of 1 mM EGTA or 1 mM 
CaCI,. Incubations were carried out with aspirin-treated platelets in the 
presence of apyrase (0.1 U ADPase/ml), where indicated (ASA/APY). 
Areas under the recorded [Ca?+],/time curves were determined to obtain 
CMP values. Data are mean valuesCSE (n)  of 3-5 experiments with 
platelets from different blood donors. n.d., not determined. 
Agonist CMP with CaCI, CMP with ECTA 
nM . s 
a-Thrombin 1093002 13200 ( 5 )  151005 300 ( 5 )  
a-Thrombin + ASA/APY 94000-+ 5200 ( 5 )  n.d. 
SFLLRN 30000 -C 300 ( 5 )  7200 5 1000 ( 5 )  
ADP 90002 200 (3) 41002 400 ( 3 )  
U46619 83002 1000 (3) 45005 600 (3) 
We first studied several factors determining the CMP of L(- 
thrombin and SFLLRN. In the presence of extracellular CaCl,, 
the increase in [Ca’+], evoked by 10 nM a-thrombin was much 
higher and more prolonged than with extracellular EGTA 
(Fig. IA).  Measurements of the [CaZ+], time integrals gave CMP 
values that were about seven-times higher when external CaCl, 
was present (Fig. 1 B). Determination of the CMP at various a- 
thrombin concentrations resulted in dose/effect plots that satu- 
rated at about 40 nM a-thrombin both in the presence and ab- 
sence of CaCI, (Fig. 1 C). The peptide SFLLRN elicited Caz+ 
responses of much shorter duration than those with a-thrombin 
(Fig. 1 D). Accordingly, this resulted in relatively low CMP val- 
ues even at a saturating concentration of 100 pM SFLLRN 
(Fig. 1 E-F). In platelets from five different donors, the maxi- 
mal CMP with high a-thrombin was on average 109000 nM . s 
and 15 100 nM s in the presence of external CaC1, and EGTA, 
respectively, while that with high SFLLRN was 30000 nM . s 
and 7000 nM . s (Table 1). Typically, especially with a-thrombin, 
considerable differences were found in the CMP of platelets 
from various individuals. 
To investigate the contribution of endogenously released 
ADP and thromboxane A, to the high and prolonged CaZ+ signal 
with a-thrombin/CaCl,, we measured the CMP in the presence 
of ADP-degrading apyrase with platelets treated with the cyclo- 
oxygenase inhibitor, aspirin. This resulted in a small reduction 
of the CMP of about 15% (Table 1). Thus, the high CMP of a -  
thrombin was not primarily caused by CaZ+ signals evoked by 
released ADP or thromboxane. This was confirmed by the obser- 
vation that even saturating doses of U46619 (1 pM) or ADP 
(20 pM) elicited short [Ca2+], transients with low CMP values 
(Table 1). 
To determine whether the sustained CaZ ’ influx-driven re- 
sponse of a-thrombin is detectable in individual platelets, we 
measured the Ca2+ responses of single platelets immobilized on 
fibinogen in the presence of RGDS and apyrase to prevent spon- 
taneous (i.e. fibrinogen adhesion-dependent) activation [23, 291. 
In the absence of agonist, 97% of the bound platelets remained 
low in [Ca’+],, and many responded to 0.5 nM a-thrombin 
(71 %) or 50 pM SFLLRN (85%) by repetitive spiking in 
[Ca’+],, when external CaCI, was present. The duration of the 
spiking signal was in these cells much longer with a-thrombin 
than with SFLLRN (Fig. 2), which is in agreement with the cell 
suspension experiments. 
The CMP at varying concentrations of a-thrombin or 
SFLLRN. There is good evidence that the continuous presence 
300 
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Fig.2. Duration of CaZ+ response evoked by a-thrombin or SFLLRN 
in single platelets. Fura-2-loaded platelets were immobilized and acti- 
vated with 0.5 nM a-thrombin or 50 pM SFLLRN in the presence of 
1 mM CaCIz, as indicated. Changes in the 340 nmi380 nm fluorescence 
ratio (-) are given, indicative of changes in [Ca’+],, of one platelet 
representative of > 50 platelets. Time integrals of accumulative increases 
in fluorescence ratio (- - -) are also shown. 
of a-thrombin is required to obtain a full Ca2+ response in plate- 
lets [18]. In agreement with this, we observed with platelets in 
suspension that a-thrombin-evoked Ca2+ signals were immedi- 
ately abrogated upon addition of the active-site inhibitors 
antithrombin 111 (1 pM) or FRP chloromethylketone (0.2 pM). 
When added at 1 min after a-thrombin, these inhibitors reduced 
the remaining CMP by 90.6?2.6% and 88.3 ?2.0%, respec- 
tively (mean ? SE, n = 3). 
We then questioned whether platelets may also respond to 
increasing concentrations of a-thrombin or SFLLRN. In a first 
set of experiments, the platelets were stimulated with a low dose 
of 1 nM a-thrombin that was followed by a higher dose of 
10 nM (Fig. 3A). This resulted in CMP values that were a factor 
of 8.3 2 0.4 (mean ? SE, n = 3) higher with the high concentra- 
tion. Similar results were obtained upon sequential addition of 
2.5 pM and 25 pM SFLLRN (Fig. 3 B). In other experiments, a- 
thrombin was gradually added to the platelets using a motor- 
driven perfusion pump. a-Thrombin infusion at a low rate of 
1.5 nM/min resulted in a lower but more prolonged increase in 
[Ca’+], than infusion at 4.0 nM/min (Fig. 3C and D). Neverthe- 
less, CMP values at the end of the experiment were almost iden- 
tical under either condition, i.e. 101 000 ? 4600 nM . s and 
108 100 t 7300 nM . s, respectively (mean 2 SE, n = 3 individ- 
uals). Within each experiment with platelets from the same do- 
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Fig.3. Effect of increasing Concentrations of a-thrombin or SFLLRN on Ca" responses in platelets in suspension. (A, B) Suspensions of fura- 
2-loaded platelets (2X1OX/2 ml) were activated in the presence of 1 mM CaC1, by rapid mixing with successively 1 nM and 10 nM a-thrombin (a- 
Thr), or with 2.5 pM and 25 mM SFLLRN, as indicated. (C, D) Platelet suspensions containing 1 mM CaCl, were mixed with a-thrombin that was 
gradually added at a rate of 1.5 nM/min (C) or 4 nMhii i  (D). Continuous lines give changes in cytosolic [Caz+],, after correction for the leakage 
of fura-2 dye out of the platelets. Discontinuous lines represent changes in a-thrombin concentration. Numbers in italic are CMP values at the end 
of the CaZ+ response (in nM . s). Data are representative for 3-5 independent experiments. 
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Fig. 4. Effect of increasing or decreasing concentration of a-thrombin on Caz+ responses in single platelets. (A, B) Fura-2-loaded platelets 
immobilized on fibrinogen were activated with 0.2 nM and 10 nM a-thrombin (a-Thr) in the presence of 1 mM CaCl,, as indicated. (C, D) Immobi- 
lized platelets were stimulated with 10 nM a-thrombin in the presence of 1 mM CaCl,, after which 1 pM antithrombin 111 (AT-111) was added. 
Similar results were obtained when 1 pM hirudin was used instead of antithrombin 111. Traces represent changes in the 340 n d 3 8 0  nm fluorescence 
ratio (-) or time integrals of accumulative increases in fluorescence ratio (- . . -) of individual cells (A, C), or are averaged data from 17 to 30 
cells (B, D). Data are representative for three or more exoeriments. 
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Fig. 5. Effects of in-situ-generated a-thrombin on Ca2+ responses in 
platelets in suspension. Fura-2-loaded platelets (2X 1OX/2 ml) were in- 
cubated with factor Va (1.35 nM) and CaCl, (2 mM) under stirring at 
37°C. Factor Xa was added at a concentration of 0.45 nM (A) or 
0.01 nM (B). Prothrombinase activation was started 2 min later by addi- 
tion of 0.5 pM prothrombin (PT). (A, B) Changes in [Ca’+], were re- 
corded and corrected for leakage of fura-2. Samples were taken at regu- 
lar times to determine the a-thrombin concentration (0). (C) Time plots 
are given of areas under [Ca2+],/time curves as determined by the integ- 
ral, Jd [CaZi];.,dt. Maximal values reached by this integral represent the 
CMP of a-thrombin at the end of the experiment. Data are representative 
for three independent experiments. 
nor, the difference in CMP values between slow and more rapid 
infusion was only 7 5 3 % .  Infusion of SFLLRN at rates of 
4 pM/min or 10 pM/min (with final concentrations of 25 pM) 
also resulted in comparable CMP values of 12500 ? 1000 nM s 
and 18 500 2 1200 nM . s, respectively (mean 2 SE, n = 3 in- 
dividuals). These results thus suggest that a-thrombin- and 
SFLLRN-induced Ca” signaling is only slightly influenced by 
previous responses to lower concentration of agonist. 
The capability to respond to varying a-thrombin levels may 
or may not be a property of single platelets in the population. 
To investigate this, platelets on fibrinogen were incubated with 
low and then higher a-thrombin concentrations. Most cells 
(78%) responded to the higher a-thrombin concentration by ad- 
ditional trains of [Ca”’], spikes of high frequency (Fig. 4 A  and 
B). It also appeared that the spiking was dependent on the con- 
tinuous presence of active a-thrombin, since in 42 out of 60 
analyzed cells, it was rapidly abolished with antithrombin 111 or 
hirudin (Fig. 4 C  and D). 
The CMP of a-thrombin generated in situ by activation of 
prothrombinase. Another way to expose platelets to gradually 
increasing a-thrombin concentrations is by incubation with the 
coagulation factors Va and Xa and prothrombin. It has been 
shown that suspensions of washed platelets contain sufficient 
procoagulant membrane surface to support activation of the 
prothrombinase complex and, thus, to generate a-thrombin in 
situ [27]. Platelet incubation with 2 mM CaCl,, 1.35 nM factor 
Va, 0.45 nM factor Xa, and 0.5 pM prothrombin resulted in a 
rapid formation of a-thrombin with an initial rate of I nM/s and 
reaching a concentration of 420 nM a-thrombin after 15 min 
(Fig. 5A). The formation of a-thrombin was accompanied by a 
potent increase in [Ca”],, after which [Ca’+], returned to almost 
basal level after 5 min. When this experiment was performed 
with a lower concentration of 0.01 nM factor Xa, this resulted 
in a 20-times slower rate of a-thrombin formation (0.05 nM/s) 
reaching an end level of 33 nM after 15 min, and in a lower but 
more prolonged rise in [Caz+]l (Fig. 5B) .  The integral, 
j”d [Ca2+],,,dt, thus reached its maximum at a later time, when 
factor Xa was low (Fig. 5C). Nevertheless, final CMP values 
were similar under conditions of high and low factor Xa concen- 
tration, i.e. 98 OOO? 6100 nM . s and 89700 ? 14600 nM . s, re- 
spectively (mean? SE, n = 3 individuals). Within each experi- 
ment using platelets from one donor, these values differed with 
only 11 ? 6%. Control experiments showed that omission of one 
of the components of the prothrombinase complex (factor Va or 
Xa or prothrombin) prevented a-thrombin formation, while 
[Caz+], remained low. In the presence of high factor Xa, a- 
thrombin formation was reduced by the addition of 1 pM 
antithrombin 111 to 23.922.3% of the control value, while the 
CMP was reduced to 49.1 ? 7.8% (mean 5 SE, n = 3). 
Effects of in-situ-generated a-thrombin were also studied on 
single platelets by activating prothrombinase with procoagulant 
phospholipid vesicles, factors Va and Xa, and prothrombin. In a 
typical experiment, 51 of 66 analyzed platelets started to show 
[Ca”], spikes soon after the first appearance of a-thrombin, and 
many of these cells showed progressively increasing Ca2+ sig- 
nals while a-thrombin was accumulating (Fig. 6 A  and B). Upon 
addition of antithrombin 111, spiking in [CaZ+], terminated in 
most (74%) of the responding platelets (Fig. 6 C  and D), indicat- 
ing that the spikes were secondary to a-thrombin formation. 
Effects of a-thrombin concentration and time on the CMP. 
The data described so far suggest that the CMP of a-thrombin 
is determined by two factors: the agonist concentration (Figs 1, 
3 and 4) and the time it is present (Figs4 and 6). For experi- 
ments where the a-thrombin level was varied, we evaluated the 
combined effects of a-thrombin concentration and time by con- 
structing plots of the time-integral of the Caz+ response as a 
function of the time-integral of the a-thrombin concentration. 
Regardless of whether a-thrombin was added by infusion (see 
Fig. 3) or whether it was formed in situ (see Fig. 5), these plots 
were independent of the rate of a-thrombin infusion or formation 
(Fig. 7). 
DISCUSSION 
a-Thrombin has a high CMP because it evokes a prolonged 
Ca” signal. To quantify the Ca2+ concentration and time charac- 
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Fig. 6. Effect of in-situ-generated a-thrombin on CaZ+ responses in single platelets. Fura-2-loaded platelets were immobilized, and incubated 
with phospholipid vesicles (2 pM), factor Va (0.24 nM), factor Xa (0.1 nM), and CaC1, (2 mM). Activation was started by the addition of prothrombin 
(0.5 pM). Where indicated, 1 pM antithrombin I11 (AT-111) was given after the addition of prothrombin. Traces represent changes in 340 n d 3 8 0  nm 
fluorescence ratio (-) or time integrals of accumulative increases in fluorescence ratio (---). Responses are shown of individual cells (A, C), 
or of averages from 15 or 33 cells (B, D). Data are representative for three experiments (>200 platelets). 
teristics of Ca2' responses evoked by a-thrombin and other 
platelet agonists, we determined time integrals of the increases 
in [Caz+l,, sd [Ca2+],,,dt. The CMP of an agonist was defined as 
the maximal value reached by this integral at the end of the 
response. With a-thrombin, SFLLRN and compounds activating 
purinergic or thromboxane receptors, the rises in [Caz+], were 
completely transient, suggesting that the Ca2+-ATPases present 
in the plasma membrane and endomembranes are fully active in 
antagonizing these Ca2+ signals. The assumption can then be 
made that the [Ca2+],-time integral primarily reflects the number 
of mobilized Caz+ ions, and not the rate by which these ions are 
pumped out of the cytosol by Ca2+-ATPases. In other words, the 
half-life time of every mobilized Caz+ ion is likely to be equal. 
Since these agonists evoke repetitive spiking in [Ca"], in single 
platelets, where rapid increases in [CaZ+], are always followed 
by rapid decreases [23], this assumption seems to be valid for 
the conditions of study. 
With saturating doses of proteolytically active a-thrombin, 
much higher CMP values are obtained than with high SFLLRN, 
ADP, or U46619. This is true for incubations carried out in the 
presence of EGTA, where the Ca" signal is exclusively caused 
by mobilization of Ca2+ from intracellular stores (Table 1). 
However, this difference is most obvious (a factor 4-10) in the 
presence of extracellular CaCI,, when influx of external Caz+ 
also contributes to the Ca" signal. With CaCl,, a-thrombin typi- 
cally evokes a high Ca2+ response of quite long duration 
(Fig. 1 A), although this is subjected to considerable donor-to- 
donor variation (Table 1). Accordingly, the high CMP of a- 
thrombin is largely due to a prolonged Ca2+ influx-driven com- 
ponent of the Ca" signal. It is probably not a consequence of 
the release of ADP or thromboxane from activated platelets, be- 
cause treatment of platelets with aspirin or apyrase gives only 
slightly decreased CMP values. This is in agreement with the 
rather low CMP values measured after stimulation of the pu- 
rinergic or thromboxane receptors with ADP or U46619, respec- 
tively (Table 1). 
The a-thrombin-evoked Ca2+ signal is determined by the in- 
stantaneous a-thrombin level. The high and prolonged Ca2+ 
signal of a-thrombin is highly sensitive to changes in a-thrombin 
concentration during the course of the Ca2+ response. For in- 
stance, increases in [Caz+], change with the a-thrombin concen- 
tration, when increasing amounts of a-thrombin are added to 
platelets by either sequential addition (Fig. 3 A) or continuous 
infusion (Fig. 3 C and D). Conversely, the CMP of a-thrombin 
is reduced with thrombin active-site inhibitors, such as 
antithrombin 111 or FPR chloromethylketone (see text). In single, 
immobilized platelets, sequential addition of increasing amounts 
of a-thrombin results in an increased frequency of spiking in 
[Ca"], (Fig. 4A and B), whereas active-site inhibitors terminate 
the spiking with a-thrombin (Fig. 4C  and D). Similar results are 
obtained when a-thrombin is continuously increased by reconsti- 
tuted prothrombinase, using purified factor Xa, factor Va, and 
prothrombin. Individual platelets respond to the accumulation of 
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Fig.7. Effects of concentration and time of a-thrombin on CaZ+ re- 
sponses in platelets in suspension. Data from the experiments shown 
in Fig. 3C and D and Fig. SA and B were used to construct plots of 
[Caz+],/time integrals, Jd[Ca2+], ,dt, as a function of the time integrals 
of the a-thrombin concentration, J[thrombin],dt. (A) Platelets were acti- 
vated by addition of u-thrombin at a rate of 1.5 nM/min (-) or 4 nM/ 
min (---), as described for Fig. 3. (B) Platelets were activated by in- 
situ-generated a-thrombin in the presence of 0.01 nM (-) or 0.45 nM 
(---) factor Xa, as described for Fig. 5. For each condition, nearly over- 
lapping curves were obtained in at least two other experiments with 
platelets from various donors, although the maximal CMP values could 
differ by 25% from one experiment to another. 
in-situ-generated a-thrombin by accelerated spiking in [Ca"],, 
and spiking stops when antithrombin I11 is added (Fig. 6). 
The observation that (single) platelets continuously respond 
to increasing and decreacing concentrations of a-thrombin leads 
to the conclusion that a-thrombin has an instantaneous effect on 
the generation of the Ca2+ signal, implying that its continuous 
proteolytic activity is required to maintain the Ca2+ response. 
For instance, antithrombin 111, hirudin, and FRP chloromethyl- 
ketone all have immediate, reducing effects on the Ca2 ' signal 
of (single) platelets (Figs 4 and 6). However, we have also found 
that the maximal CMP with saturating a-thrombin (> 10 nM) 
is essentially insensitive to the rate of a-thrombin infusion or 
formation in situ (Fig. 3C  and D and Fig. 5C). This suggests 
that the (prolonged) Ca2+ signal of a-thrombin is not or only 
slightly subjected to homologous desensitization due to previous 
a-thrombin activity. Since CMP values of SFLLRN are also in- 
dependent of the infusion rate, this lack of desensitization may 
be a property of the concerned protease-activated receptors : ap- 
parently, the Ca2+ signal of newly activated receptor molecules 
is not influenced by that of previously activated receptors. 
There is good evidence for the existence of SFLLRN-insen- 
sitive a-thrombin receptors on platelets [7- 11, 131. Although 
glycoprotein Ib complexes [ 10, 111 and a second protease-acti- 
vated receptor [I31 have been put forward, the identity of the 
alternative receptors is still unclear. Our data also advocate the 
presence of more than one receptor type. Saturating doses of a- 
thrombin have a much higher maximal CMP than SFLLRN be- 
cause of a higher and more sustained influx of external Ca2+. 
While this confirms the idea that part of the a-thrombin-evoked 
Ca2+ signal is not mediated by type 1 protease-activated recep- 
tors [9-111, the results also suggest that the signaling is com- 
pletely dependent on proteolytic activity. This supports the pro- 
posal of Hayes et al. [12], that a-thrombin activates platelets 
solely because of its enzymatic nature. Although glycoprotein 
Ib is highly sensitive to proteolysis [I I], it remains to be investi- 
gated whetherhow cleavage of this glycoprotein may be respon- 
sible for part of the a-thrombin-evoked Ca2+ signal. 
The cumulative CaZ+ response with a-thrombin is determined 
by the product of a-thrombin concentration and time. If a- 
thrombin activates platelets mainly by a proteolytic mechanism, 
its activating effect should be a function of both the a-thrombin 
concentration and the time it is present. We measured that the 
cumulative Ca2+ response of platelets is a function of the time 
integral of the a-thrombin concentration, independent of the rate 
at which a-thrombin accumulates (Fig. 7). In other words, the 
product of a-thrombin concentration and time defines the integ- 
rated Ca" signal over that time. From these considerations, it is 
tempting to conclude that the time integral of the a-thrombin 
concentration defines the number of receptor cleavages leading 
to Ca2+ mobilization. This closely resembles the earlier reported 
effects of a-thrombin on fibroblasts transfected with mutated 
thrombin receptors, where it was found that cumulative receptor 
cleavage by a-thrombin correlates with cumulative phospholi- 
pase C activity and it was concluded that every cleaved receptor 
produces a fixed quantum of second messengers [5, 211. Our 
data similarly suggest that cleavage of the natural thrombin re- 
ceptors on platelets results in fixed quanta of Caz+ mobilization 
and Ca2+ influx. Thus, the a-thrombin concentration at a certain 
time may determine the rate of receptor cleavage and thereby 
the number of Ca2+ quanta mobilized at that moment, whereas 
the time during which a-thrombin is active may determine the 
total number of cleaved receptors and thus the total number of 
Ca" quanta (the integrated Ca2+ signal). 
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